Human Bhsp90 As Adjuvant in Hcv Recombinant Vaccine

There are more than 350 million individuals with hepatitis c in the world. one of the important problems in vaccine project is development of effective and suitable adjuvant in human vaccines. at present research we applied human bhsp90 protein as an adjuvant in recombinant hcv vaccine design. the thermal vector of pgp1-2 was used for human heat shock protein 90 expression. this protein injected to balbc mice as an adjuvant together with recombinant protein of hcv core. the combination of these proteins was used and we evaluated the humoral and cellular immunity and the cytokine secretion of inguinal and popliteal lymph nodes lymphocytes were analyzed in vitro and ex vivo conditions. so the combination of core protein together with hsp90 induced total igg and igg2a secretion. the spleen lymphocytes proliferation were increased equal to serum igg2a level that was constant in second time bleeding with significant different to complexes with freund’s adjuvant. at first il-4 and il-5 cytokines were increased, after one week it decreased. production of il-4 showed there was no hypersensitivity reaction after vaccine injection